Time New York: Mon 22 Oct 04:03 am  |  Save 15% on H&R Block Online

  
caticonslite_bm_alt

BD Completes Asset Divestitures to Merit Medical

BD Completes Asset Divestitures to Merit Medical

Divestitures Satisfy All Contingencies from Regulatory Authorities Related to Acquisition of C. R. Bard, Inc.

PR Newswire

FRANKLIN LAKES, N.J., Feb. 15, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it has completed the previously announced divestitures of its soft tissue core needle biopsy product line and Aspira product line to Merit Medical Systems, Inc. following receipt of all required regulatory approvals for such divestitures.

 (PRNewsfoto/BD (Becton, Dickinson and Compa)


The completion of the divestitures satisfies the remaining contingencies within the previously received regulatory approvals in the U.S., Europe and China for BD’s acquisition of C. R. Bard, Inc., which was completed on Dec. 29, 2017.

This sale will not have a material impact on revenue or earnings for fiscal 2018.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to better diagnose disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com.

Contacts:

Troy Kirkpatrick

Monique N. Dolecki

BD Public Relations

BD Investor Relations

858.617.2361

201.847.5378

troy.kirkpatrick@bd.com

Monique_Dolecki@bd.com

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/bd-completes-asset-divestitures-to-merit-medical-300598804.html

SOURCE BD (Becton, Dickinson and Company)

<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.